NEW YORK (GenomeWeb) – T2 Biosystems reported after the close of the market Tuesday a rise in its fourth quarter net loss amid increased costs associated with promoting its Candida test T2Candida and development of new assays, although it still topped Wall Street expectations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.